We serve Chemical Name:1-(4-Chlorobenzyl)-2-thiourea CAS:24827-37-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-(4-Chlorobenzyl)-2-thiourea
CAS.NO:24827-37-0
Synonyms:(4-chlorophenyl)methylthiourea
Molecular Formula:C8H9ClN2S
Molecular Weight:200.68800
HS Code:2930909090
Physical and Chemical Properties:
Melting point:142-144ºC
Boiling point:333.1ºC at 760 mmHg
Density:1.323g/cm3
Index of Refraction:1.646
PSA:70.14000
Exact Mass:200.01700
LogP:2.76440
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (4-chlorophenyl)methylthiourea chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-chlorophenyl)methylthiourea physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4-chlorophenyl)methylthiourea Use and application,(4-chlorophenyl)methylthiourea technical grade,usp/ep/jp grade.
Related News: Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System. 1-(4-Chlorobenzyl)-2-thiourea manufacturer Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System. 1-(4-Chlorobenzyl)-2-thiourea supplier Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System. 1-(4-Chlorobenzyl)-2-thiourea vendor The survival benefit is “unprecedented” for an aging myeloma population, almost all of whom were 65 years of age or older, said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 1-(4-Chlorobenzyl)-2-thiourea factory Darzalex has its own VRd combo trials, dubbed PERSEUS and CEPHEUS, which are testing a newly approved under-the-skin version of the J&J drug called Darzalex Faspro. The CEPHEUS trial appears to have just completed its primary analysis, according to a listing on ClinicalTrials.gov.
